GoAI
Get started
Prelude Therapeutics Incorporated logo

Prelude Therapeutics Incorporated

PRLD

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$6.63

+$0.13 · +2.00%

Aug 21, 4:00 PM ET

PRLD company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

63

Undervalued

Momentum

73

Gaining

Sentiment

70

Bullish

Risk resilience

49

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Krishna Vaddi
Listed since
Sep 25, 2020
Employees
79

Market position

Day range

Current $6.63

52-week range

Current $6.63

Open
$6.60
Previous close
$6.50
Volume
519.21K
1.07× average
Average volume
485.59K
Average daily volume
Market cap
377.46M USD
Beta
0.94
Market reference 1
50-day average
$4.7342
+40.04% above average
200-day average
$3.3973
+95.16% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
144.4M USD
P/E (TTM)
-8.39×
P/B (TTM)
4.88×
P/S (TTM)
16.83×
EV / EBITDA
-1.48×
Earnings yield
-44.58%
Free cash flow yield
-25.26%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
98.26%
Operating margin
-300.56%
Net margin
-269.75%
Return on equity
-144.96%
Return on assets
-70.41%
Return on invested capital
-114.83%

Financial health

Debt / equity
0.13×
Current ratio
1.99×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends310%-529%-1367%-2206%Gross margin, FY2024: 100.00%Gross margin, FY2025: 85.91%Operating margin, FY2024: -1995.91%Operating margin, FY2025: -861.33%Net margin, FY2024: -1816.76%Net margin, FY2025: -819.59%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2024 100.00%. Gross margin FY2025 85.91%. Operating margin FY2024 -1995.91%. Operating margin FY2025 -861.33%. Net margin FY2024 -1816.76%. Net margin FY2025 -819.59%.

Income trends

Revenue

12.14M USD+73.43%

Operating income

−104.57M USD+25.16%

Net income

−99.5M USD+21.76%
Income trends across reported periods27.33M USD−33.42M USD−94.16M USD−154.9M USDRevenue, FY2024: 7M USDRevenue, FY2025: 12.14M USDOperating income, FY2021: −113.74M USDOperating income, FY2022: −123.54M USDOperating income, FY2023: −132.28M USDOperating income, FY2024: −139.71M USDOperating income, FY2025: −104.57M USDNet income, FY2021: −111.69M USDNet income, FY2022: −115.44M USDNet income, FY2023: −121.83M USDNet income, FY2024: −127.17M USDNet income, FY2025: −99.5M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2024 7M USD. Revenue FY2025 12.14M USD. Operating income FY2021 −113.74M USD. Operating income FY2022 −123.54M USD. Operating income FY2023 −132.28M USD. Operating income FY2024 −139.71M USD. Operating income FY2025 −104.57M USD. Net income FY2021 −111.69M USD. Net income FY2022 −115.44M USD. Net income FY2023 −121.83M USD. Net income FY2024 −127.17M USD. Net income FY2025 −99.5M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue12.14M USD7M USD———
Cost of goods sold1.71M USD————
Gross profit10.43M USD7M USD———
Research and development94.3M USD118M USD103.39M USD92.89M USD86.78M USD
Selling, general, and administrative22.41M USD28.72M USD28.88M USD30.65M USD26.96M USD
Operating expenses115M USD146.71M USD132.28M USD123.54M USD113.74M USD
Depreciation and amortization1.71M USD1.77M USD1.17M USD1.32M USD915K USD
Operating income−104.57M USD−139.71M USD−132.28M USD−123.54M USD−113.74M USD
Net income−99.5M USD−127.17M USD−121.83M USD−115.44M USD−111.69M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
91%
10 beats, 0 misses, 1 met estimate
Average EPS surprise
+19.53%
11 comparable reports
Latest EPS result
-0.14
Estimate -0.2 · Beat by 28.81%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.11-0.25-0.39-0.53Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 10, 2025: actual -0.38, estimate -0.49, surprise +22.45%, Beat. Q2 2025, reported May 6, 2025: actual -0.42, estimate -0.47, surprise +10.64%, Beat. Q3 2025, reported Aug 14, 2025: actual -0.41, estimate -0.45, surprise +8.89%, Beat. Q4 2025, reported Nov 12, 2025: actual -0.26, estimate -0.35, surprise +25.71%, Beat. Q1 2026, reported Mar 10, 2026: actual -0.2, estimate -0.33, surprise +39.39%, Beat. Q2 2026, reported May 12, 2026: actual -0.13, estimate -0.27, surprise +51.85%, Beat. Q3 2026, reported Aug 11, 2026: actual -0.14, estimate -0.197, surprise +28.81%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.16, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates37.92M26.13M14.34M2.55MQ1 '24No estimateQ4 '24No estimateQ1 '25No estimateQ4 '25MissQ1 '26MissQ2 '26MetQ3 '26MetQ4 '26Estimate
Q1 2024, reported Feb 15, 2024: actual 3.42M USD, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 6, 2024: actual 3M USD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 10, 2025: actual 4M USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 12, 2025: actual 6.5M USD, estimate 20.5M USD, surprise -68.29%, Miss. Q1 2026, reported Mar 10, 2026: actual 5.6M USD, estimate 20.5M USD, surprise -72.68%, Miss. Q2 2026, reported May 12, 2026: actual 4.58M USD, estimate 4.58M USD, surprise 0.00%, Met estimate. Q3 2026, reported Aug 11, 2026: actual 5.7M USD, estimate 5.7M USD, surprise 0.00%, Met estimate. Q4 2026, reported Nov 11, 2026: actual —, estimate 35.33M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$8.00

20.66% upside
Past 12 months12-month forecastHigh $8.00Average $8.00Low $8.00

Rating distribution

8 ratings
Strong buy00%
Buy563%
Hold113%
Sell225%
Strong sell00%

PRLD news

zacks.com

Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?

The consensus price target hints at a 58.4% upside potential for Prelude Therapeutics (PRLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate…

Read source
defenseworld.net

ADAR1 Capital Management LLC Makes New Investment in Prelude Therapeutics Incorporated $PRLD

ADAR1 Capital Management LLC purchased a new position in shares of Prelude Therapeutics Incorporated (NASDAQ: PRLD) during the undefined quarter, according to the company in its most recent Form 13F filing with the…

Read source
zacks.com

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why

Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read source
seekingalpha.com

Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Read source

PRLD peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding PRLD

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
6.96M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
4.21M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.11M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
1.69M
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
715.26K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
612.97K
Weight
0.04%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Vanguard Russell 2000 Growth ETF logoVanguard Russell 2000 Growth ETFVTWG
Market value
138.01K
Weight
0.01%
AUM
1.7B USD
Expense ratio
0.06%
Price / 1D
$282.73+1.21%
Invesco Russell 2000 Dynamic Multifactor ETF logoInvesco Russell 2000 Dynamic Multifactor ETFOMFS
Market value
127.77K
Weight
0.05%
AUM
285.96M USD
Expense ratio
0.39%
Price / 1D
$53.21+0.87%

Continue in GoAI

Research PRLD

research.disclaimer